Form 4: Eli Lilly Director Acquires Shares Under 10b5-1 Plan

Eli Lilly & Co. Director William G. Kaelin Jr. acquired 215.327 shares of common stock at $1,021.7 per share under a pre-arranged trading plan.

Summary

• Director William G. Kaelin Jr. of Eli Lilly & Co. acquired 215.327 shares of common stock.
• The transaction is reported to occur on November 17, 2025, at a price of $1,021.7 per share.
• Following this acquisition, William G. Kaelin Jr. directly owns 21,836.814 shares of Eli Lilly & Co. common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) pre-arranged trading plan.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director, especially under a 10b5-1 plan, generally indicates confidence in the company's future prospects. While not a major transaction, it's a positive signal.

Positives

• A director acquiring shares can be seen as a positive signal, indicating confidence in the company's future prospects.
• The acquisition was part of a Rule 10b5-1 plan, which suggests a pre-planned, systematic approach to share ownership rather than a reactive trade.

Future Outlook

This filing reports an insider transaction and does not contain forward-looking statements or guidance regarding the company's future performance.

Industry Context

Insider buying, especially by a director, can be interpreted as a sign of confidence in the company's future performance within the pharmaceutical industry, which is often subject to long development cycles and regulatory approvals.

Comparison to Industry Standards

• Insider transactions are common across all industries.
• The use of a 10b5-1 plan is a standard practice for corporate insiders to manage their stock transactions while avoiding accusations of trading on material non-public information.
• The size of the acquisition (215.327 shares) relative to the director's total holdings (21,836.814 shares) represents a modest increase in ownership.

Corporate Governance

Related Party Transactions

• The acquisition of common stock by Director William G. Kaelin Jr. is a related party transaction.

Stakeholder Impact

• Shareholders may view the director's acquisition as a positive signal of confidence in the company's future.

Key Dates

Recommendation

The acquisition of shares by Director William G. Kaelin Jr. under a 10b5-1 plan is a positive indicator of management confidence. However, this single transaction, while supportive, is not substantial enough on its own to alter a fundamental investment thesis. Investors should consider this alongside broader financial performance and market conditions.

Keywords

Eli Lilly, LLY, Form 4, Insider Trading, Stock Acquisition, Director, William G. Kaelin Jr., 10b5-1 Plan, Pharmaceuticals